590 related articles for article (PubMed ID: 28273375)
1. Characteristics of patients receiving ustekinumab compared with secukinumab for treatment of moderate-to-severe plaque psoriasis - nationwide results from the DERMBIO registry.
Egeberg A; Iversen L; Gniadecki R; Hvid L; Dam TN; Bryld LE; Skov L
J Eur Acad Dermatol Venereol; 2017 Jul; 31(7):1183-1187. PubMed ID: 28273375
[TBL] [Abstract][Full Text] [Related]
2. Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate-to-severe plaque psoriasis: 52-week results from the CLEAR study.
Blauvelt A; Reich K; Mehlis S; Vanaclocha F; Sofen H; Abramovits W; Zhao Y; Gilloteau I; Davenport E; Williams N; Guana A; Tyring S
J Eur Acad Dermatol Venereol; 2017 Oct; 31(10):1693-1699. PubMed ID: 28602039
[TBL] [Abstract][Full Text] [Related]
3. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study.
Blauvelt A; Reich K; Tsai TF; Tyring S; Vanaclocha F; Kingo K; Ziv M; Pinter A; Vender R; Hugot S; You R; Milutinovic M; Thaçi D
J Am Acad Dermatol; 2017 Jan; 76(1):60-69.e9. PubMed ID: 27663079
[TBL] [Abstract][Full Text] [Related]
4. Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis.
Egeberg A; Ottosen MB; Gniadecki R; Broesby-Olsen S; Dam TN; Bryld LE; Rasmussen MK; Skov L
Br J Dermatol; 2018 Feb; 178(2):509-519. PubMed ID: 29094341
[TBL] [Abstract][Full Text] [Related]
5. Clinical and economic review of secukinumab for moderate-to-severe plaque psoriasis.
Wong IT; Shojania K; Dutz J; Tsao NW
Expert Rev Pharmacoecon Outcomes Res; 2016; 16(2):153-66. PubMed ID: 26681527
[TBL] [Abstract][Full Text] [Related]
6. Effect of secukinumab on quality of life and psoriasis-related symptoms: A comparative analysis versus ustekinumab from the CLEAR 52-week study.
Puig L; Augustin M; Blauvelt A; Gottlieb AB; Vender R; Korman NJ; Thaçi D; Zhao Y; Gilloteau I; Sherif B; Williams N; Guana A; Lebwohl MG
J Am Acad Dermatol; 2018 Apr; 78(4):741-748. PubMed ID: 29066271
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of sequential biologic therapy with ixekizumab versus secukinumab as first-line treatment of moderate-to-severe psoriasis in the UK.
Johansson EC; Hartz S; Kiri SH; Kumar G; Svedbom A
J Med Econ; 2018 Aug; 21(8):810-820. PubMed ID: 29873270
[TBL] [Abstract][Full Text] [Related]
8. Secukinumab: a review in moderate to severe plaque psoriasis.
Garnock-Jones KP
Am J Clin Dermatol; 2015 Aug; 16(4):323-330. PubMed ID: 26202871
[TBL] [Abstract][Full Text] [Related]
9. Secukinumab significantly reduces psoriasis-related work impairment and indirect costs compared with ustekinumab and etanercept in the United Kingdom.
Warren RB; Halliday A; Graham CN; Gilloteau I; Miles L; McBride D
J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2178-2184. PubMed ID: 29846965
[TBL] [Abstract][Full Text] [Related]
10. Twelve-week secukinumab treatment is consistently efficacious for moderate-to-severe psoriasis regardless of prior biologic and non-biologic systemic treatment: Post hoc analysis of six randomised trials.
Hampton P; Halliday A; Aassi M; Subramanian S; Jain M; Griffiths CEM
J Eur Acad Dermatol Venereol; 2021 Apr; 35(4):928-937. PubMed ID: 33030755
[TBL] [Abstract][Full Text] [Related]
11. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.
Thaçi D; Blauvelt A; Reich K; Tsai TF; Vanaclocha F; Kingo K; Ziv M; Pinter A; Hugot S; You R; Milutinovic M
J Am Acad Dermatol; 2015 Sep; 73(3):400-9. PubMed ID: 26092291
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of secukinumab vs. ustekinumab for treatment of psoriasis on quality of life, work productivity and activity impairment: a structural equation modelling analysis.
Stull DE; Griffiths CEM; Gilloteau I; Zhao Y; Guana A; Finlay AY; Sherif B; Houghton K; Puig L
Br J Dermatol; 2018 Jun; 178(6):1297-1307. PubMed ID: 29355896
[TBL] [Abstract][Full Text] [Related]
13. Number needed to treat and costs per responder among biologic treatments for moderate-to-severe plaque psoriasis in Japan.
Imafuku S; Nakano A; Dakeshita H; Li J; Betts KA; Guerin A
J Dermatolog Treat; 2018 Feb; 29(1):24-31. PubMed ID: 28608740
[TBL] [Abstract][Full Text] [Related]
14. A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis.
Bilal J; Berlinberg A; Bhattacharjee S; Trost J; Riaz IB; Kurtzman DJB
J Dermatolog Treat; 2018 Sep; 29(6):569-578. PubMed ID: 29532693
[TBL] [Abstract][Full Text] [Related]
15. Randomized Trial Replication Using Observational Data for Comparative Effectiveness of Secukinumab and Ustekinumab in Psoriasis: A Study From the British Association of Dermatologists Biologics and Immunomodulators Register.
Yiu ZZN; Mason KJ; Hampton PJ; Reynolds NJ; Smith CH; Lunt M; Griffiths CEM; Warren RB;
JAMA Dermatol; 2021 Jan; 157(1):66-73. PubMed ID: 33263718
[TBL] [Abstract][Full Text] [Related]
16. Secukinumab treatment of moderate to severe plaque psoriasis in routine clinical care: real-life data of prior and concomitant use of psoriasis treatments from the PROSPECT study.
Körber A; Thaçi D; von Kiedrowski R; Bachhuber T; Melzer N; Kasparek T; Kraehn-Senftleben G; Amon U; Augustin M
J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):411-419. PubMed ID: 28960469
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and safety of secukinumab in 69 patients with moderate to severe plaque psoriasis: A retrospective multicenter study.
Schwensen JF; Clemmensen A; Sand C; Gniadecki R; Skov L; Zachariae C; Iversen L; Rasmussen M; Thomsen SF
Dermatol Ther; 2017 Nov; 30(6):. PubMed ID: 28906051
[TBL] [Abstract][Full Text] [Related]
18. Switching from Secukinumab to Ustekinumab in Psoriasis Patients: Results from a Multicenter Experience.
Chiricozzi A; Conti A; Burlando M; Odorici G; Gaiani F; Panduri S; Malagoli P
Dermatology; 2019; 235(3):213-218. PubMed ID: 30928971
[TBL] [Abstract][Full Text] [Related]
19. Lower Limbs are the Most Difficult-to-Treat Body Region of Patients with Psoriasis: Pooled Analysis of CLEAR and CLARITY Studies of Secukinumab Versus Ustekinumab by Body Region.
Alpalhão M; Duarte J; Diogo R; Vandemeulebroecke M; Ortmann CE; Kasparek T; Filipe P
BioDrugs; 2022 Nov; 36(6):781-789. PubMed ID: 36334236
[TBL] [Abstract][Full Text] [Related]
20. Secukinumab demonstrates superior efficacy and a faster response in clearing skin in Asian subjects with moderate to severe plaque psoriasis compared with ustekinumab: Subgroup analysis from the CLEAR study.
Lee MG; Huang YH; Lee JH; Lee SC; Kim TG; Aw DC; Bao W; Dee CMA; Guana A; Tsai TF
J Dermatol; 2019 Sep; 46(9):752-758. PubMed ID: 31342560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
